NEW YORK--(BUSINESS WIRE)--DellaCamera Capital Management, LLC (“DCM”), a shareholder owning in excess of 6% of Nabi Biopharmaceuticals (NASDAQ: NABI) common stock, today sent a letter to the Board of Directors of Nabi expressing their belief that the Company’s stock is reflecting an irrationally low value for Nabi’s assets, which include the Company’s novel NicVAX nicotine addiction compound. DCM believes that the Company has the flexibility to pursue an aggressive share repurchase program in light of this low valuation while not jeopardizing its ability to further NicVAX development and partnering discussions.
